Document Detail

Breast cancer survival and season of surgery: an ecological open cohort study.
Jump to Full Text
MedLine Citation:
PMID:  22223841     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Background Vitamin D has been suggested to influence the incidence and prognosis of breast cancer, and studies have found better overall survival (OS) after diagnosis for breast cancer in summer-autumn, where the vitamin D level are expected to be highest. Objective To compare the prognostic outcome for early breast cancer patients operated at different seasons of the year. Design Open population-based cohort study. Setting Danish women operated 1978-2010. Cases 79 658 adjusted for age at surgery, period of surgery, tumour size, axillary lymph node status and hormone receptor status. Statistical analysis The association between OS and season of surgery was analysed by Cox proportional hazards regression models, at survival periods 0-1, 0-2, 0-5 and 0-10 years after surgery. A two-sided p value <0.05 was considered statistical significant. Results Only after adjustment for prognostic factors that may be influenced by vitamin D, 1-year survival was close to significantly associated season of surgery. 2, 5 and 10 years after surgery, the association between OS and season of surgery was not significant. Limitations Season is a surrogate measure of vitamin D. Conclusions The authors found no evidence of a seasonal variation in the survival after surgery for early breast cancer. Lack of seasonal variation in this study does not necessarily mean that vitamin D is of no importance for the outcome for breast cancer patients.
Authors:
Dorthe Teilum; Karsten D Bjerre; Anne M Tjønneland; Niels Kroman
Publication Detail:
Type:  Journal Article     Date:  2012-01-05
Journal Detail:
Title:  BMJ open     Volume:  2     ISSN:  2044-6055     ISO Abbreviation:  BMJ Open     Publication Date:  2012  
Date Detail:
Created Date:  2012-01-06     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101552874     Medline TA:  BMJ Open     Country:  England    
Other Details:
Languages:  eng     Pagination:  e000358     Citation Subset:  -    
Affiliation:
Brystkirurgisk Klinik PBB, Copenhagen, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): BMJ Open
Journal ID (publisher-id): bmjopen
Journal ID (hwp): bmjopen
ISSN: 2044-6055
Publisher: BMJ Group, BMA House, Tavistock Square, London, WC1H 9JR
Article Information
Download PDF
© 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
open-access:
Received Day: 30 Month: 9 Year: 2011
Accepted Day: 1 Month: 12 Year: 2011
collection publication date: Year: 2012
Electronic publication date: Day: 5 Month: 1 Year: 2012
pmc-release publication date: Day: 5 Month: 1 Year: 2012
Volume: 2 Issue: 1
E-location ID: e000358
ID: 3253416
PubMed Id: 22223841
Publisher Id: bmjopen-2011-000358
DOI: 10.1136/bmjopen-2011-000358

Breast cancer survival and season of surgery: an ecological open cohort study Alternate Title:Breast cancer survival and season of surgery
Dorthe Teilum1
Karsten D Bjerre2
Anne M Tjønneland3
Niels Kroman1
1Brystkirurgisk Klinik PBB, Copenhagen, Denmark
2Danish Breast Cancer Cooperative Group, Copenhagen, Denmark
3Danish Cancer Society, Institute of Cancer Epidemiology, Copenhagen, Denmark
Correspondence: Correspondence to Dr Dorthe Teilum; dorthe.teilum@rh.regionh.dk
[other] We will be pleased to share the necessary data for the statistical review of our paper. However, it is not possible for us to make the entire data material public available.

Introduction

Over the past decades, ecological studies have inspired to the hypothesis that exposure to sunlight and hence difference in serum vitamin D may influence both risk and prognosis for breast cancer.1, 2 The hypothesis has been supported by several in vitro and animal studies,3, 4 in addition to case–control and cohort studies with measurements of vitamin D as serum 25 hydroxy-vitamin D (25(OH)D),5–15 although not all studies including two meta-analyses could support these findings.16–19 Four studies found the prognosis of breast cancer to vary with the season for diagnosis. The three of them found that patients diagnosed in summer–autumn had a better disease outcome than those diagnosed in winter–spring,20–22 and one study found a higher overall mortality for patients diagnosed in late summer compared with those diagnosed in mid-winter.23

In Denmark, positioned at 55–58° northern latitude, there is no sufficient sun to synthesise vitamin D in the human skin during 6–8 months of the year. Measurements of vitamin D in healthy Danish volunteers demonstrate a pronounced seasonal variation of vitamin D with a maximum in late summer and a minimum in early spring, which indicates that the content of vitamin D in the average Danish diet could not compensate for the lack of sun-induced vitamin D production during wintertime.24

If the vitamin D status at the time of the operation is important for the overall survival (OS), it should be both easy and inexpensive to adjust preoperatively. The aim of this study is to compare the prognostic outcome for early breast cancer patients diagnosed and operated at different seasons of the year based on a large population-based registration of women with breast cancer in Denmark including detailed information on prognostic factors.


Materials and methods

The Danish Breast Cancer Cooperative Group (DBCG) founded in 1977 is a population-based registry, which collects data on almost all cases of invasive breast cancer among residents in Denmark (a population of 5.5 million, emigration and immigration rates <2%) (http://www.dst.dk). Virtually, all involved Danish hospital departments have applied DBCG's guidelines for diagnostic procedures, surgery, radiotherapy, adjuvant systemic therapy and follow-up for early breast cancer. Diagnostic, therapeutic and follow-up data have been accumulated prospectively in the DBCG registry by the use of standardised forms. The DBCG Data Center applied the same procedures for all patients, including monitoring and analysis of data, whether or not the patients participated in randomised trials.25

Cases

The present analysis includes all women, who had a completely resected invasive carcinoma of the breast and no signs of distant metastasis as determined by routine examinations (physical examination, clinical chemistry, chest radiography and other examinations if indicated). Cases with bilateral breast cancer were included (n=1535), and the tumour characteristics of the side with the least favourable prognostic impact were recorded in the DBCG registry. A negative sentinel node biopsy or axillary clearance (levels I and II) in combination with breast-conserving surgery or mastectomy was required. Radiotherapy to the breast was mandatory following lumpectomy. Further description of the database and treatment guidelines has been given elsewhere.25, 26

From 1 June 1978 to 31 May 2010, 89 409 cases were registered. Of these, 3113 had a diagnosis of previous breast cancer, other malignancy (except non-melanoma skin tumours) or distant metastasis and 610 patients were not operated. Further excluded from the analyses were patients with unknown tumour size (n=2045) and/or unknown axillary lymph node status (n=5678). In total, 79 658 cases were included for further analyses (figure 1).

Variables

The seasons of surgery, generally 1–3 weeks after the diagnosis, were defined as follows: winter (1 December to 28 or 29 February), spring (1 March to 31 May), summer (1 June to 31 August) and autumn (1 September to 30 November), so the summer period includes the months with the possibility of most sun exposure due to the altitude of the sun and vacations. Treatment periods were categorised according to the national programmes initiated in 1977, 1982, 1989, 1999, 2001, 2004 and 2007.25 The age at surgery was categorised in intervals: ≤39, 40–49, 50–59, 60–69, 70–79 and ≥80 years. Tumour size was categorised according to the largest tumour diameter: 0–10, 11–20, 21–50 and ≥51 mm. The spread of breast cancer to locoregional lymph nodes was categorised as negative, one to three positive lymph nodes and four or more positive lymph nodes. The hormone receptor status was categorised as: negative, oestrogen receptor or progesterone receptor positive and unknown. The histopathological status was categorised in five groups as: grade I, II or III ductal carcinoma, lobular carcinoma and carcinoma of other types or unknown diagnosis. The frequency of allocated systemic treatment (chemotherapy and endocrine therapy) by season of surgery was reported.

End point

OS was measured from the date of surgery to the date of death. Observations were censored at emigration or at 1 June 2011, which was the date of data withdrawal of patient vital status from the Danish Centralised Civil Register.

Statistical analysis

The association between OS and season of surgery was analysed by Cox proportional hazards regression models.27, 28 The effects of season of surgery were analysed in models with an increasing level of adjustment for prognostic variables: models stratified by treatment programme (adjusted I); models stratified by treatment programme and age at surgery (adjusted II) and models stratified by treatment programme, age at surgery, hormone receptor status and lymph node status and further including the effects of tumour size and histological type (fully adjusted). The interpretations of a seasonal effect on survival in these models differ according to the level of adjustment. In the fully adjusted model, the seasonal effect includes the effects of unknown or not included prognostic variables including the alleged effect of vitamin D. In the adjusted II model, the seasonal effect includes the effects of both known and unknown prognostic variables. In the adjusted I model, the seasonal effect further includes the effects of referral pattern, that is, patient age at surgery. The stratification of the Cox models was chosen to meet the proportional hazards assumption as assessed by Schoenfeld residuals plots.27 The analyses were done for four survival periods: 0–1, 0–2, 0–5 and 0–10 years after surgery. The null hypothesis of no survival effect of season of surgery was assessed by the Wald χ2 statistic, and a two-sided p value <0.05 was considered statistically significant. The HRs of season of surgery (winter as reference level) together with their 95% CIs are reported. Due to the long period of inclusion, the potential heterogeneity of seasonal effects according to period of inclusion was investigated in models including an interaction term of season of surgery and programme series (1977 and 1982 vs 1989 vs 1999, 2001, 2004 and 2007). Analysis was performed with SAS V.9.1 (SAS Institute).


Results

The person-years of observation were 78 587 for the survival period 0–1 years, 151 980 for the survival period 0–2 years, 327 646 for the survival period 0–5 years and 516 011 for the survival period 0–10 years after surgery. For the latter group, the median observation period for patients without an event was 10.0 year. The basic characteristics of the patient material according to season of surgery are presented in table 1.

HRs of OS up to 10 years with surgery performed in winter as reference are given in table 2. Overall, no statistically significant association between OS and season of surgery are observed in 2-, 5- and 10-year follow-up periods. Only for the 1-year follow-up, a close to significant association is observed (p=0.052, fully adjusted analysis); OS is highest for patients undergoing surgery in autumn (HR: 0.97, 95% CI 0.86 to 1.09) and lowest for patients undergoing surgery in summer (HR: 1.12, 95% CI 1.00 to 1.26). Heterogeneity of seasonal effects according to period of inclusion was not statistical significant irrespective of model adjustment or survival period.


Discussion

In the present study, we found no evidence of a seasonal variation in the OS among almost 80 000 Danish women with primary breast cancer. The strengths of this study are the sample size, the population-based approach in a limited geographic area,29 the prospectively collected characteristics of tumour and lymph node status and the long follow-up (median 10.0 years). The detailed information's offer the possibility of including season of surgery in a multivariate analysis with the variables year, age at surgery, tumour size, nodal status, hormone receptor status and histopathological type. It should be noted that in our analysis, the ‘adjusted II’ models are stratified by treatment programme and age at surgery only. Thus, the estimates of association between OS and seasonal of surgery are not affected by the variables potentially associated with vitamin D or season of surgery (tumour size, positive axillary nodes, high-grade tumours and oestrogen receptor/progesterone receptor status). Using this approach, the independent prognostic effect of season of surgery seems to disappear. The limitations of the study are the lack of information about serum vitamin D in the individual patient at the time of surgery. Using the estimated UV dose as surrogate for vitamin D status must cause reservation, as it is not known whether vitamin D status of the breast cancer patients follow that of the background population. Lack of seasonal variation in this study does not necessarily mean that vitamin D is not important for the OS for breast cancer patients. The serum vitamin D in Danish women treated for breast cancer could be so low even among patients treated in the summer–autumn so that no difference could be detected. One nested case–control study (N=142) showed lower serum vitamin D among Danish patients at the diagnostic mammography.14 Cross-sectional studies of the plasma vitamin D in healthy Danish volunteers demonstrate a higher level in summer–autumn than in winter–spring.24

Results from UK and Norway indicate a better prognosis if diagnosis of breast cancer takes place during the summer or autumn.20–22 This seasonal variation was interpreted as a result of vitamin D deficiency in the dark months of the year, although one author considered the possibility that the seasonal effect might be due to a relative higher rate of diagnoses in summer and the prevalence of infections during wintertime leading to early death.20 In contrast, results from Sweden demonstrate a worse OS for patients diagnosed in the summer probably due to a relative reduction in the number of early stage diagnoses from mammography screening which are closed in the summer months and the healthcare system treating primarily the most sick patients in holiday periods.23, 30 Breast cancer is regarded as a relatively slow growing cancer, with a long preclinical course.31 If vitamin D level should be of etiologic or prognostic importance, it is supposed that the influence is working over a longer time period and not just reflected by vitamin D status at time of diagnosis. If the level of vitamin D at the time of surgery should influence prognosis, the mechanism must be differences in perioperative resistance to cancer dissemination and the logical precaution would be to ensure a high preoperative vitamin D level. However, limited evidence including the present study supports this statement.



Notes

To cite: Teilum D, Bjerre KD, Tjønneland AM, et al. Breast cancer survival and season of surgery: an ecological open cohort study. BMJ Open 2012;2:e000358. doi:10.1136/bmjopen-2011-000358

Funding:This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests: All authors have completed the ICMJE disclosure form (available on request from the corresponding author) and declare: no support from any organisation for the submitted work, no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years and no other relationships or activities that could appear to have influenced the submitted work.

Ethics approval: The data are from Danish Breast Cancer Group.

Contributors: DT contributed to conception and interpretation of data, reviewed the literature, drafted the article and finally approved the submitted paper. KDB analysed and interpreted the data, drafted the statistical part and finally approved the submitted paper. AMT and NK contributed to the interpretation of data, revised it critically for important intellectual contents and finally approved the submitted paper.

Provenance and peer review: Not commissioned; externally peer reviewed.

References
1. Kricker A,Armstrong B. Does sunlight have a beneficial influence on certain cancers?Prog Biophys Mol BiolYear: 2006;92:132–916595142
2. van der Rhee HJ,de Vries E,Coebergh JW. Does sunlight prevent cancer? A systematic review. Eur J CancerYear: 2006;42:2222–3216904314
3. Thorne J,Campbell MJ. The vitamin D receptor in cancer. Proc Nutr SocYear: 2008;67:115–2718412986
4. Welsh J. Vitamin D and prevention of breast cancer. Acta Pharmacol SinYear: 2007;28:1373–8217723171
5. Abbas S,Linseisen J,Slanger T,et al. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer–results of a large case-control study. CarcinogenesisYear: 2008;29:93–917974532
6. Bertone-Johnson ER. Vitamin D and breast cancer. Ann EpidemiolYear: 2009;19:462–719230714
7. Chen P,Hu P,Xie D,et al. Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res TreatYear: 2010;121:469–7719851861
8. Crew KD,Gammon MD,Steck SE,et al. Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prev Res (Phila Pa)Year: 2009;2:598–604
9. Garland CF,Garland FC,Gorham ED,et al. The role of vitamin D in cancer prevention. Am J Public HealthYear: 2006;96:252–6116380576
10. Goodwin PJ,Ennis M,Pritchard KI,et al. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin OncolYear: 2009;27:3757–6319451439
11. Kim HJ,Lee YM,Ko BS,et al. Vitamin D deficiency is correlated with poor outcomes in patients with luminal-type breast cancer. Ann Surg OncolYear: 2011;18:1830–621573699
12. Palmieri C,MacGregor T,Girgis S,et al. Serum 25-hydroxyvitamin D levels in early and advanced breast cancer. J Clin PatholYear: 2006;59:1334–617046848
13. Perez-Lopez FR,Chedraui P,Haya J. Review article: vitamin D acquisition and breast cancer risk. Reprod SciYear: 2009;16:7–1919144887
14. Rejnmark L,Tietze A,Vestergaard P,et al. Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case-control study. Cancer Epidemiol Biomarkers PrevYear: 2009;18:2655–6019789365
15. Vrieling A,Hein R,Abbas S,et al. Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study. Breast Cancer ResYear: 2011;13:R7421791049
16. Chlebowski RT,Johnson KC,Kooperberg C,et al. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer InstYear: 2008;100:1581–9119001601
17. Freedman DM,Chang SC,Falk RT,et al. Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers PrevYear: 2008;17:889–9418381472
18. Gandini S,Boniol M,Haukka J,et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J CancerYear: 2011;128:1414–2420473927
19. Yin L,Grandi N,Raum E,et al. Meta-analysis: serum vitamin D and breast cancer risk. Eur J CancerYear: 2010;46:2196–20520456946
20. Lim HS,Roychoudhuri R,Peto J,et al. Cancer survival is dependent on season of diagnosis and sunlight exposure. Int J CancerYear: 2006;119:1530–616671100
21. Porojnicu AC,Lagunova Z,Robsahm TE,et al. Changes in risk of death from breast cancer with season and latitude: sun exposure and breast cancer survival in Norway. Breast Cancer Res TreatYear: 2007;102:323–817028983
22. Robsahm TE,Tretli S,Dahlback A,et al. Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes ControlYear: 2004;15:149–5815017127
23. Holmberg L,Adolfsson J,Mucci L,et al. Season of diagnosis and prognosis in breast and prostate cancer. Cancer Causes ControlYear: 2009;20:663–7019067189
24. Mosekilde L,Nielsen LR,Larsen ER,et al. [Vitamin D deficiency. Definition and prevalence in Denmark]. Ugeskr LaegerYear: 2005;167:29–3315675161
25. Moller S,Jensen MB,Ejlertsen B,et al. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta OncolYear: 2008;47:506–2418465317
26. Ejlertsen B,Jensen MB,Rank F,et al. Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer. J Natl Cancer InstYear: 2009;101:729–3519436035
27. Schoenfeld D. Partial residuals for the proportional hazards regression model. BiometrikaYear: 2011;69:239–41
28. Kalbfleisch JD,Prentice RL. The Statistical Analysis of Failure Time Data. John Wiley.
29. Kimlin MG. Geographic location and vitamin D synthesis. Mol Aspects MedYear: 2008;29:453–6118786559
30. Lambe M,Blomqvist P,Bellocco R. Seasonal variation in the diagnosis of cancer: a study based on national cancer registration in Sweden. Br J CancerYear: 2003;88:1358–6012778061
31. Gullino PM. Natural history of breast cancer. Progression from hyperplasia to neoplasia as predicted by angiogenesis. CancerYear: 1977;39(6 Suppl):2697–703326375

Figures

[Figure ID: fig1]
Figure 1 

Flow diagram: prospective registration of Danish women operated for early breast cancer 1978–2010. *Except non-melanoma skin tumours.



Tables
[TableWrap ID: tbl1] Table 1 

Prognostic factors by season among 79 658 Danish women operated for early breast cancer between 1 June 1978 and 31 May 2010


Characteristic Winter
Spring
Summer
Autumn
Total
n % n % n % n % n %
Total 18 760 20 067 20 033 20 798 79 658
Age at surgery*
 ≤39 years 1051 5.6 1057 5.3 1001 5.0 1094 5.3 4203 5.3
 40–49 years 3249 17.3 3604 18.0 3524 17.6 3637 17.5 14 014 17.6
 50–59 years 4906 26.2 5251 26.2 5232 26.1 5461 26.3 20 850 26.2
 60–69 years 5203 27.7 5506 27.4 5520 27.6 5702 27.4 21 931 27.5
 70–79 years 3233 17.2 3436 17.1 3541 17.7 3642 17.5 13 852 17.4
 ≥80 years 1118 6.0 1213 6.0 1215 6.1 1262 6.1 4808 6.0
Period of surgery
 1977–1989 4592 24.5 4783 23.8 5115 25.5 5448 26.2 19 938 25.0
 1990–1999 5626 30.0 6160 30.7 6359 31.7 6559 31.5 24 704 31.0
 2000–2010 8542 45.5 9124 45.5 8559 42.7 8791 42.3 35 016 44.0
Tumour size
 0–10 mm 2832 15.1 3136 15.6 2972 14.8 3211 15.4 12 151 15.3
 11–20 mm 7419 39.5 7983 39.8 7945 39.7 8310 40.0 31 657 39.7
 21–50 mm 7469 39.8 7964 39.7 8053 40.2 8201 39.4 31 687 39.8
 >50 mm 1040 5.5 984 4.9 1063 5.3 1076 5.2 4163 5.2
Nodal status§
 Negative 9767 52.1 10 672 53.2 10 723 53.5 11 233 54.0 42 395 53.2
 1–3 positive 5772 30.8 5984 29.8 5915 29.5 6015 28.9 23 686 29.7
 ≥4 positive 3221 17.2 3411 17.0 3395 16.9 3550 17.1 13 577 17.0
Histological group
 Ductal grade I 4808 25.6 5129 25.6 5242 26.2 5390 25.9 20 569 25.8
 Ductal grade II/?** 7268 38.7 7672 38.2 7542 37.6 7893 38.0 30 375 38.1
 Ductal grade III 3351 17.9 3504 17.5 3517 17.6 3626 17.4 13 998 17.6
 Lobular 1963 10.5 2135 10.6 2086 10.4 2137 10.3 8321 10.4
 Other invasive 1370 7.3 1627 8.1 1646 8.2 1752 8.4 6395 8.0
ER–PgR status
 Negative 2919 15.6 3176 15.8 3299 16.5 3217 15.5 12 611 15.8
 Positive 12 453 66.4 13 054 65.1 12 994 64.9 13 849 66.6 52 350 65.7
 Unknown 3388 18.1 3837 19.1 3740 18.7 3732 17.9 14 697 18.5
Per cent Er–PgR positive††, ‡‡ 81.0 80.4 79.8 81.1 80.6
Adjuvant systemic therapy
 None 9449 50.4 10 256 51.1 10 551 52.7 10 940 52.6 41 196 51.7
 Chemotherapy§§ 4749 25.3 5063 25.2 4849 24.2 5043 24.2 19 704 24.7
 Endocrine therapy¶¶ 6270 33.4 6629 33.0 6347 31.7 6654 32.0 25 900 32.5

*χ2=12.2, df=15, p=0.66.

χ2=80.7, df=6, p=0.0001.

χ2=14.9, df=9, p=0.09.

§χ2=19.5, df=6, p=0.003.

χ2=25.1, df=12, p=0.014.

**Unknown grade, n=1533.

††Positive relative to sum of positive and negative.

‡‡χ2=12.7, df=3, p=0.005.

§§χ2=11.7, df=3, p=0.009.

¶¶χ2=18.4, df=3, p=0.0004.

ER, oestrogen receptor; PgR, progesterone receptors.


[TableWrap ID: tbl2] Table 2 

Overall survival by Cox proportional hazards regression at survival periods 0–1, 0–2, 0–5 and 0–10 years post-surgery


Period of follow-up Adjusted I*
Adjusted II
Fully adjusted
Season of surgery HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
0–1 years after surgery
 Winter 1 (reference) 0.053 1 (reference) 0.067 1 (reference) 0.052
 Spring 1.07 (0.95 to 1.20) 1.06 (0.95 to 1.19) 1.07 (0.96 to 1.20)
 Summer 1.09 (0.97 to 1.22) 1.08 (0.96 to 1.21) 1.12 (1.00 to 1.25)
 Autumn 0.95 (0.84 to 1.06) 0.94 (0.84 to 1.06) 0.97 (0.86 to 1.09)
0–2 years after surgery
 Winter 1 (reference) 0.19 1 (reference) 0.17 1 (reference) 0.43
 Spring 0.99 (0.92 to 1.06) 0.98 (0.92 to 1.06) 1.00 (0.93 to 1.07)
 Summer 0.99 (0.92 to 1.06) 0.99 (0.92 to 1.06) 1.01 (0.94 to 1.08)
 Autumn 0.93 (0.87 to 1.00) 0.93 (0.86 to 1.00) 0.96 (0.89 to 1.03)
0–5 years after surgery
 Winter 1 (reference) 0.60 1 (reference) 0.48 1 (reference) 0.96
 Spring 0.98 (0.94 to 1.03) 0.98 (0.94 to 1.03) 1.00 (0.95 to 1.04)
 Summer 0.98 (0.94 to 1.02) 0.97 (0.93 to 1.02) 1.00 (0.95 to 1.04)
 Autumn 0.97 (0.93 to 1.01) 0.97 (0.93 to 1.01) 0.99 (0.95 to 1.03)
0–10 years after surgery
 Winter 1 (reference) 0.90 1 (reference) 0.81 1 (reference) 0.92
 Spring 1.00 (0.96 to 1.03) 1.00 (0.96 to 1.03) 1.01 (0.98 to 1.05)
 Summer 1.00 (0.96 to 1.03) 0.99 (0.96 to 1.03) 1.01 (0.98 to 1.05)
 Autumn 0.99 (0.95 to 1.02) 0.98 (0.95 to 1.02) 1.00 (0.97 to 1.04)

Estimates of season of surgery are shown among 79 658 Danish women operated for breast cancer between 1 June 1978 and 31 May 2010.

*Model stratified for treatment programme.

Model stratified for treatment programme and age at surgery.

Model stratified for treatment programme, age at surgery, hormone receptor status and nodal status and including the effects of tumour size and histological group.



Article Categories:
  • Surgery
    • Research
Article Categories:
  • 1506
  • 1717
  • 1737


Previous Document:  A cost-effectiveness analysis of an in-hospital clinical pharmacist service.
Next Document:  Randomised controlled trial evaluating the efficacy of wrap therapy for wound healing acceleration i...